Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fehling

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Metabolism: Clinical and Experimental|May 27, 2008
Moderate protein intake improves total and regional body composition and insulin sensitivity in overweight adultsPaul J Arciero, Christopher L Gentile, Roger Pressman, et al.
Ebiomedicine|May 26, 2019
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsAubrey L Miller, Samuel C Fehling, Patrick L Garcia, et al.
Cancers|July 24, 2021
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic CancerAubrey L Miller, Patrick L Garcia, Samuel C Fehling, et al.
Glia|January 31, 2018
MicroRNA-31 is required for astrocyte specificationGordon P Meares, Rajani Rajbhandari, Magda Gerigk, et al.
Cancer Letters|August 19, 2018
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancerKelly M Kreitzburg, Samuel C Fehling, Charles N Landen, et al.
Oncotarget|July 13, 2015
Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastomaRajani Rajbhandari, Braden C McFarland, Ashish Patel, et al.
Cancer Letters|May 4, 2024
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabineAubrey L Miller, Samuel C Fehling, Rebecca B Vance, et al.
Protein Science : a Publication of the Protein Society|July 2, 2015
Comparison of intrinsic dynamics of cytochrome p450 proteins using normal mode analysisMariah E Dorner, Ryan D McMunn, Thomas G Bartholow, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Metabolism: Clinical and Experimental|May 27, 2008
Moderate protein intake improves total and regional body composition and insulin sensitivity in overweight adultsPaul J Arciero, Christopher L Gentile, Roger Pressman, et al.
Ebiomedicine|May 26, 2019
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsAubrey L Miller, Samuel C Fehling, Patrick L Garcia, et al.
Cancers|July 24, 2021
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic CancerAubrey L Miller, Patrick L Garcia, Samuel C Fehling, et al.
Glia|January 31, 2018
MicroRNA-31 is required for astrocyte specificationGordon P Meares, Rajani Rajbhandari, Magda Gerigk, et al.
Cancer Letters|August 19, 2018
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancerKelly M Kreitzburg, Samuel C Fehling, Charles N Landen, et al.
Oncotarget|July 13, 2015
Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastomaRajani Rajbhandari, Braden C McFarland, Ashish Patel, et al.
Cancer Letters|May 4, 2024
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabineAubrey L Miller, Samuel C Fehling, Rebecca B Vance, et al.
Protein Science : a Publication of the Protein Society|July 2, 2015
Comparison of intrinsic dynamics of cytochrome p450 proteins using normal mode analysisMariah E Dorner, Ryan D McMunn, Thomas G Bartholow, et al.
Pageof 6